Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
Open accessThe DOI matches its Crossref record; 103 of the 107 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) have emerged as novel therapeutic agents for T2DM, primarily aiming to reduce blood glucose levels. However, recent investigations have unveiled their multifaceted effects, extending beyond their glucose-lowering effect. SGLT2i operate by inhibiting the SGLT2 receptor in the kidneys, facilitating the excretion of glucose through urine, leading to reduced blood glucose levels, while GLP1-RA mimic the action of the GLP1 hormone, stimulating glucose-dependent insulin secretion from pancreatic islets. Both SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM. This comprehensive review explores the expanding horizons of SGLT2i and GLP1-RA in improving cardiovascular health. It delves into the latest research, highlighting the effects of these drugs on heart physiology and metabolism. By elucidating their diverse mechanisms of action and emerging evidence, this review aims to recapitulate the potential of SGLT2i and GLP1-RA as therapeutic options for cardiovascular health beyond their traditional role in managing T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These agents not only improve glycemic control but also deliver robust cardiovascular and renal protection, with additional anti-inflammatory and antioxidative effects that modify the underlying pathophysiology of cardiometabolic disease [2,3].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373 · cited 1×
“ATP synthesis is crucial for the proper functioning of cardiomyocytes, and its production is impaired in failing hearts [64].”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 5×
“Subsequently, retatrutide entered a phase 2 clinical trial, aiming to develop it for the treatment of T2DM, obesity, and related comorbidities [101,103].”
InfluentialRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784 · cited 1×
“The increased utilization of FFA leads to an increment in lipolysis, promoting a reduction in inflammation mediated by adipose tissue, decreased oxidative stress and its damages, and reduced levels of circulating uric acid [57,58].”
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · cited 2×
“GIP receptor agonists belong to the same receptor family and Both compounds bind to their respective receptors on pancreatic β -cells, stimulating insulin secretion glucose-dependently [92,93].”
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
Diabetes and hypertension: the bad companions
Ferrannini, E., & Cushman, W. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60987-8 · Cited by 695 · cited 1×
“In addition, hyperinsulinemia causes vascular remodeling by promoting the proliferation of vascular smooth muscle and other cells, thereby reducing vascular stiffness [81].”
Cited by
Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02319-7 · Cited by 72
“GLP1RAs can inhibit neutral lipid accumulation, ROS generation, and (NADPH oxidase 4) NOX-4 expression in rat cardiomyocytes, thereby migrating interleukin-1 β (IL-1 β) induced ROS production [57].”
BackgroundMericskay, M., Zuurbier, C. J., Heather, L. C., Karlstaedt, A., Inserte, J., Bertrand, L., Kararigas, G., Ruiz‐Meana, M., Maack, C., & Schiattarella, G. G. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01166-7 · Cited by 79
Mitochondrial Dysfunction in Atrial Fibrillation: The Need for a Strong Pharmacological Approach
Mauriello, A., Correra, A., Molinari, R., Vecchio, G. E. D., Tessitore, V., D’Andrea, A., & Russo, V. (2024) · Biomedicines · doi:10.3390/biomedicines12122720 · Cited by 27
“Fibrates, acting as PPAR-alfa agonists, are commonly utilized to address hypertriglyceridemia, decrease hepatic apolipoprotein C-III (apoC-III) levels, and enhance lipoprotein lipase-mediated lipolysis.”
Little, P. J., Offermanns, S., Cho, H., Liu, Z., Yang, P., Su, Q., Wade, H., Yang, W., Kamato, D., Cohen, N. D., et al. (2026) · iNew Medicine · doi:10.1002/inm3.70028 · Cited by 27
Yang, Y., Liu, W., Zhang, Z., zhang, Y., Wang, X., Wang, J., Cai, H., Liu, Y., Meng, R., Fu, Y., et al. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103414 · Cited by 19
Metadata
- Authors
- Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., Genovese, S., & Poggio, P.
- Affiliations
- Centro Cardiologico Monzino (IT)
- Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy
- University of Salerno (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Poggio, Paolo
- ORCID
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2023-12-20
- Volume
- 13
- Issue
- 1
- Pages
- 16
- ISSN
- 2076-3921 (ISSN-L)
- PMC
- PMC10812629
- OpenAlex
- W4389991782
- Cited by
- 35
- References
- 107
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 10
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antioxidants (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (PNRR-MAD-2022-12376009, FPF-14)
- Italian Ministry of Health (Ricerca Corrente to Centro Cardiologico Monzino IRCCS) (PNRR-MAD-2022-12376009, FPF-14)
- Fondazone Gigi & Pupa Ferrari ONLUS (PNRR-MAD-2022-12376009, FPF-14)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, cardiovascular disease, anti-inflammatory activity, antioxidant activity, cardioprotection, glucose-lowering therapy, cardiac physiology, myocardial metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. https://app.cochat.ai/papers/10.3390/antiox13010016
- The paper
- Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., Genovese, S., & Poggio, P. (2023). Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. Antioxidants. https://doi.org/10.3390/antiox13010016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.